HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer

Oncogene

Volumn 32, Issue 13, 2013, Pages 1616-1625

  Kim, K ^a   Jutooru, I ^b   Chadalapaka, G ^b   Johnson, G ^b   Frank, J ^b   Burghardt, R ^b   Kim, S ^c   Safe, S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell cycle progression; HOTAIR; Invasion; Pro oncogenic; Prognostic

Indexed keywords

HOTAIR; LONG UNTRANSLATED RNA; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; REGULATOR GENE; RNA INTERFERENCE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; PANCREATIC NEOPLASMS; PROGNOSIS; RNA, LONG UNTRANSLATED; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875890253     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.193     Document Type: Article

References (46)

1. Mattick JS. Challenging the dogma: The hidden layer of non-protein-coding RNAs in complex organisms. Bioessays 2003; 25: 930-939.
2. Mattick JS. RNA regulation: A new genetics? Nat Rev Genet 2004; 5: 316-323.
3. Szymanski M, Barciszewska MZ, Erdmann VA, Barciszewski J. A new frontier for molecular medicine: Noncoding RNAs. Biochim Biophys Acta 2005; 1756: 65-75.
4. Prasanth KV, Spector DL. Eukaryotic regulatory RNAs: An answer to the 'genome complexity' conundrum. Genes Dev 2007; 21: 11-42.
5. Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC et al. Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet 2008; 17: 642-655.
6. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011; 477: 295-300.
7. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
8. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13: 1097-1101.
9. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17: 118-126.
10. Berezikov E, Plasterk RH. Camels and zebrafish, viruses and cancer: A microRNA update. Hum Mol Genet 2005; 14 Spec No. 2: R183-R190.
11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
12. Nelson KM, Weiss GJ. MicroRNAs and cancer: Past, present, and potential future. Mol Cancer Ther 2008; 7: 3655-3660.
13. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
14. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323.
15. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667-11672.
16. Huarte M, Rinn JL. Large non-coding RNAs: Missing links in cancer? Hum Mol Genet 2010; 19: R152-R161.
17. Spitale RC, Tsai MC, Chang HY. RNA templating the epigenome: Long noncoding RNAs as molecular scaffolds. Epigenetics 2011; 6: 539-543.
18. Costa FF. Non-coding RNAs: Meet thy masters. Bioessays 2010; 32: 599-608.
19. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142: 409-419.
20. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076.
21. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-693.
22. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F et al. Overexpression of long noncoding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243-1250.
23. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6326.
24. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 2010; 7: E1000307.
25. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008; 55: 2016-2027.
26. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-503.
27. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356-364.
28. Baek SJ, Horowitz JM, Eling TE. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 2001; 276: 33384-33392.
29. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J et al. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immunecompetent mouse models of cancer. Cancer Res 2010; 70: 4539-4549.
30. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086-5098.
31. Steen HC, Gamero AM. Interferon-l as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30: 597-602.
32. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
33. Maia CJ, Socorro S, Schmitt F, Santos CR. Characterization of oligoadenylate synthetase-1 expression in rat mammary gland and prostate: Effects of 17b-estradiol on the regulation of OAS1g in both tissues. Mol Cell Biochem 2008; 314: 113-121.
34. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res 2008; 14: 6097-6105.
35. Haller O, Kochs G, Weber F. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev 2007; 18: 425-433.
36. Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS et al. Knockdown of interferoninduced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol 2011; 103: 187-195.
37. Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M et al. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood 2009; 113: 2526-2534.
38. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011; 472: 120-124.
39. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914.
40. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl) methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptorindependent activation of early growth response-1 and nonsteroidal antiinflammatory drug-activated gene-1. Mol Pharmacol 2005; 68: 1782-1792.
41. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 2012; 31: 1034-1044.
42. Lei P, Abdelrahim M, Cho SD, Liu X, Safe S. Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis (3'-indoly)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 2008; 7: 3363-3372.
43. Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 2010; 285: 25332-25344.
44. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007; 3: 11-17.
45. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet 2006; 38: 500-501.
46. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.